Endocrinology - Global Cardiology Academy

1-16 of 22

Could It Be FCS? Recognizing the Diagnostic Clues
Could It Be FCS? Recognizing the Diagnostic Clues
On the Frontlines of Familial Chylomicronemia Syndrome
Could It Be FCS? Recognizing the Diagnostic Clues
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA; Zahid Ahmad, MD, FNLA
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Zahid Ahmad, MD, FNLA
The Long Road to an FCS Diagnosis
The Long Road to an FCS Diagnosis
On the Frontlines of Familial Chylomicronemia Syndrome
The Long Road to an FCS Diagnosis
Charles Turck, PharmD, BCPS, BCCCP; Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
- Charles Turck, PharmD, BCPS, BCCCP
- Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
On the Frontlines of Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Steve Jackson, PharmD; Nivedita Patni, MD
- Steve Jackson, PharmD
- Nivedita Patni, MD
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart Matters
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD; Payal Kohli, MD, FACC
- Shelina Ramnarine, PhD
- Payal Kohli, MD, FACC
Is It Familial or Multifactorial Chylomicronemia Syndrome?
Is It Familial or Multifactorial Chylomicronemia Syndrome?
On the Frontlines of Familial Chylomicronemia Syndrome
Is It Familial or Multifactorial Chylomicronemia Syndrome?
Steve Jackson, PharmD; Michael D. Shapiro
- Steve Jackson, PharmD
- Michael D. Shapiro
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart Matters
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP; Anu Lala, MD
- Brian P. McDonough, MD, FAAFP
- Anu Lala, MD
- Martha Gulati, MD, MS, FACC, FAHA
Supporting Whole-Body Health Through the Gut
Supporting Whole-Body Health Through the Gut
NutritionEdge
Supporting Whole-Body Health Through the Gut
Shelina Ramnarine, PhD; Terri DeNeui, DNP, APRN, ACNP-BC
- Shelina Ramnarine, PhD
- Terri DeNeui, DNP, APRN, ACNP-BC
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Heart Matters
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Alexandria May, PharmD, BCPS; Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
- Alexandria May, PharmD, BCPS
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart Matters
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Susan Davis
- Susan Davis
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Richard E. Pratley, MD
- Richard E. Pratley, MD
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
prof. Hiddo Heerspink; Peter Rossing, MD, DMSc
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Rajiv Agarwal, MBBS, MD, FASN, BRCU; Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits

Prev
1
2
Next

1/2